Skip to content
MamaGLP — home
enes

Evidence review

The Next Generation of GLP-1s, Explained (Warmly)

Two of these four are approved and prescribable now. A warm, cited primer on the GLP-1 pills that landed and the combinations still in trials.

Written by Camila Rael, editora mom, not a clinician treating you

Every medical claim is cited to its primary source — the clinical trial or the FDA label — so you can open it and check it yourself. No one on this team is your healthcare professional. What follows is friendly information, never medical advice.

On this page

The friendly overview

If you have heard names like "the pill version" or "the triple one" and felt a little lost, this page is for you. The GLP-1 world is moving fast, and a few new options are coming that could make treatment easier to take or more effective. None of this changes what you should do today — that is still a conversation with your clinician — but it is genuinely nice to know where things are headed. For a baseline, today's benchmark injectable semaglutide helped adults lose close to 15% of their body weight over 68 weeks in its landmark trial1. Keep that number in your back pocket as we go, so the new arrivals have something to be compared against. And if any term trips you up, GLP-1 basics for first-timers is a gentle glossary.

The pill you swallow: oral semaglutide

The headline most moms care about: a once-daily tablet, no injection. This one is no longer coming — it arrived. Oral semaglutide was approved as Wegovy tablets on 22 December 20257, at a 25 mg dose, and the trial of that dose found roughly 14% body-weight loss3. You will also see a bigger number attached to this pill: the earlier OASIS 1 trial tested 50 mg and reported about 15% loss at 68 weeks versus about 2% on placebo2. That larger dose is not the one that was approved, so 25 mg is the number to carry. The trade-off to know: like the injections, the tablets bring gastrointestinal side effects (nausea, etc.) more often than placebo, and the tablet has particular timing rules for how you take it — an empty stomach and a wait before anything else.

The other pill, built differently: orforglipron

Orforglipron is also an oral GLP-1, but it is a small-molecule drug — chemically simpler to make than semaglutide, without the strict food-and-water timing rules, which is why a lot of people are watching it. In a large 72-week trial, its higher dose put more than half of participants past 10% body-weight loss, with a side-effect profile in line with other GLP-1 medicines4. It was approved as Foundayo on 1 April 20267, so this one has arrived too — and the promise it arrived on, an easy-to-manufacture daily pill with no timing rules, is exactly why you kept hearing the name.

The heavy hitter: retatrutide

Retatrutide is a "triple agonist" — it acts on three hormone pathways at once (GLP-1 plus GIP plus glucagon) instead of one or two. In a phase 2 trial, its highest dose produced around 24% body-weight loss at 48 weeks5 — the largest figures we have seen in this class so far. The honest caveats: this is still earlier-stage research, larger and longer trials are underway, and bigger appetite effects can come with more side effects to manage. But if you have wondered "how far can this go," retatrutide is the reason the ceiling keeps rising.

The combo: CagriSema

CagriSema pairs semaglutide with a second molecule, cagrilintide (an amylin-based drug), in one weekly injection — the idea being two complementary appetite pathways working together. In its phase 3 REDEFINE 1 trial, CagriSema produced about 20% body-weight loss at 68 weeks versus roughly 3% on placebo6. So it lands above today's single-agent semaglutide, in the same conversation as the triple agonist, as a combination approach.

How to hold all of this

A simple way to file it away: oral semaglutide and orforglipron are about convenience (a pill instead of a shot), and both are now approved; retatrutide and CagriSema are about more (bigger results by hitting more pathways), and neither is approved yet. Being approved is not the same as being affordable, though — coverage and cash prices vary widely and keep shifting, so the right question for your clinician is never "which future drug" but "what is the best option for me, right now."

A warm next step

You do not need a pharmacology degree to make a good decision — you need a clinician who knows the current options and a starting point that fits your life. To keep learning, GLP-1 myths vs. facts is a great companion to this primer. The future is bright, and you get to meet it at your own pace. — Camila

Retatrutide and CagriSema are investigational and are not approved; the two pills above are approved but may not be covered or available where you are, and coverage changes over time.*

Frequently asked questions

Is there a GLP-1 pill instead of an injection?

Yes — two of them, and both are approved. Oral semaglutide was approved as Wegovy tablets on 22 December 2025 at a 25 mg dose, where its trial found roughly 14% body-weight loss; a larger 50 mg dose was studied earlier and reported about 15%, but that is not the dose that was approved. Orforglipron was approved as Foundayo on 1 April 2026 — chemically simpler and without the strict timing rules. Coverage still varies, so ask your clinician what is offered where you are.

What is retatrutide and why do people say it works so well?

Retatrutide is a 'triple agonist' that acts on three hormone pathways at once (GLP-1, GIP, and glucagon). In a phase 2 trial its highest dose produced around 24% body-weight loss at 48 weeks — the largest figures in the class so far. It is still earlier-stage, with bigger trials underway.

What is CagriSema?

CagriSema is a once-weekly injection combining semaglutide with cagrilintide, an amylin-based molecule, so two appetite pathways work together. In its phase 3 REDEFINE 1 trial it produced about 20% body-weight loss at 68 weeks versus roughly 3% on placebo.

Should I wait for these newer medicines before starting?

Not necessarily. Availability, coverage, and approval timelines keep shifting, and today's options are effective and well studied. The better question for your clinician is what is the best choice for you right now — the pipeline is a reason for optimism, not a reason to delay.

Where this leaves you

Read the Live Vital review →Read the HumeCare+ review →Read the MadeMed review →

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/37385278/
  3. Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40934115/
  4. Wharton S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40960239/
  5. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37366315/
  6. Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40544433/
  7. U.S. Food and Drug Administration (2026). Drugs@FDA: FDA-Approved Drugs — oral semaglutide (WEGOVY tablets), NDA 218316, original approval 22 December 2025; orforglipron (FOUNDAYO), NDA 220934, original approval 1 April 2026. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Friendly information, not a prescription. Everything on MamaGLP is here to help you understand your options and ask better questions — it is not a diagnosis, not a treatment plan, and not a nudge to start or stop anything. Only a licensed healthcare professional who knows your history and your goals can tell you what is right for you, so please talk with one before acting on a single word of this.

Keep reading